FcRn-targeted therapeutics for the treatment of antibody-mediated autoimmune and albumin-mediated disease
US11471526B2 · kind B2 · utility
0Cited by
0References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 24, 2020 |
| Grant date | Oct 18, 2022 |
| Priority date | — |
| Expiry date | Feb 24, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16134
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
HCMV US11 based therapeutics that can be used to target and reduce the activity of the FcRn protein are provided. Methods of treating auto-immune mediated and albumin-mediated diseases in a subject are provided that comprise administration of HCMV US11 protein, polypeptide fragments, or variants thereof, as well as methods for preventing, or treating, infections of HCMV through administration of a US11 inhibitor. US11 protein containing vaccine compositions are also provided for stimulation of an anti-US11 immune response for protection against HCMV infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.